Form 10-K Intellia Therapeutics, For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Intellia Therapeutics (NTLA) PT Lowered to $50 at Truist Securities
March 3, 2025 11:55 AM ESTTruist Securities analyst Joon Lee lowered the price target on Intellia Therapeutics (NASDAQ: NTLA) to $50.00 (from $90.00) while maintaining a Buy rating.
The analyst comments "4Q24: Restructuring underway should help extend operational runway into 1H27 as NTLA-2002 is poised to be the historic first in... More
